The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons
The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons
复制标题
DOI：
10.1002/jbmr.5650070812
复制
发表时间：
1992-08
影响因子：
6.2
通讯作者：
D. Thompson;J. Seedor;H. Quartuccio;H. Solomon;C. Fioravanti;J. Davidson;H. Klein;R. Jackson;J. Clair;D. Frankenfield;E. Brown;H. Simmons;G. Rodan
中科院分区：
文献类型：
--
作者：
D. Thompson;J. Seedor;H. Quartuccio;H. Solomon;C. Fioravanti;J. Davidson;H. Klein;R. Jackson;J. Clair;D. Frankenfield;E. Brown;H. Simmons;G. Rodan
我们观察了氨基双膦酸阿伦磷酸酯(0.05和0.25 mg/kg，每2周一次静脉注射)对去卵巢狒狒骨丢失和骨代谢相关参数的影响。与非OVX动物相比，OVX狒狒经历了更高的骨转换，反映在生化和组织形态测量上，腰椎双光束吸收测量仪评估了骨丢失，这与卵巢切除女性的变化相似。阿伦磷酸钠治疗将骨转换的所有参数维持在对照(未去卵巢)水平，并以剂量依赖的方式防止骨丢失。我们的结论是，去卵巢的狒狒为去卵巢的妇女观察到的骨骼变化提供了一个合适的模型，并且持续给予适当剂量的氨基二磷酸盐可以防止这些变化。
We examined the effect of the amino bisphosphonate alendronate, administered IV every 2 weeks at 0.05 and 0.25 mg/kg for 1 year, on bone loss and parameters related to bone metabolism in ovariectomized baboons. Relative to non‐OVX animals, the OVX baboons experienced increased bone turnover, reflected in biochemical and histomorphometric measurements, and bone loss assessed by dual‐beam absorptiometry in the lumbar spine, which was similar to changes observed in ovariectomized women. Alendronate treatment maintained all parameters of bone turnover at control (nonovariectomized) levels and prevented the bone loss in a dose‐dependent manner. We concluded that ovariectomized baboons offer a suitable model for the bone changes observed in ovariectomized women and that these changes can be prevented by sustained administration of an appropriate dose of this aminobisphosphonate.